Loading...
•
Jun 30, 2020
Supernus Q2 2020 Earnings Report
Reported second quarter financial results and associated company developments.
Key Takeaways
Supernus Pharmaceuticals reported a strong second quarter in 2020, with total revenue reaching $126.7 million, driven by net product sales of Trokendi XR, Oxtellar XR, and acquired Parkinson’s disease products. The company also completed the acquisition of the CNS portfolio of US WorldMeds and executed a Development and Option Agreement with Navitor Pharmaceuticals, Inc.
Total revenue reached $126.7 million, including $10.6 million from acquired Parkinson’s disease (PD) products.
Operating earnings were $45.5 million.
Completed acquisition of CNS portfolio of US WorldMeds on June 9, 2020.
Reinstating and updating full year 2020 financial guidance, inclusive of the impact of acquiring the PD products as of June 9, 2020.
Revenue by Segment
Forward Guidance
Supernus is reinstating and updating its full year 2020 financial guidance, inclusive of the impact of acquiring the PD products as of June 9, 2020.
Positive Outlook
- Net product sales to range from $460 million to $500 million, including approximately $80 million from the PD products.
- Gross margins of approximately 90%.
- R&D expenses of approximately $85 million.
- Selling, general and administrative expenses to range from $240 million to $250 million.
- Operating earnings (GAAP) to range from $90 million to $110 million, which includes amortization of intangible assets of approximately $15 million.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...